85% of patients for Rare Diseases screening selected via Danny Analytics

Empowering physicians in real-time to identify eligible patients for Pompe, Gaucher, and Fabry screening via Danny Analytics AI algorithm

Sqilline and a leading pharmaceutical company have partnered to apply Big Data technologies for the screening of patients for rare diseases to expedite diagnosis by finding previously undiagnosed patients.

CHALLENGES:

  • Limited awareness of doctors, patients, and their relatives
  • Symptoms – interpreted in the context of common diseases
  • Average 4.8 Yrs. for a patient with a rare disease to reach an accurate diagnosis

BENEFITS FOR PHYSICIANS:

  • Enabling physicians quickly to identify patients for early diagnosis and timely treatment
  • Improves collaboration and awareness of the disease among the hospitals in the country
  • Better clinical and patient-oriented outcomes

WHY DANNY ANALYTICS:

  • Embedded ML algorithms allow the platform to extract and search by keywords from the enormous volume of unstructured/free text from the epicrisis
  • Using pre-defined inclusion and exclusion criteria, the eligible patients are selected in real-time
  • Automatically alert physicians when new, high-risk patients are added to an appropriate screening cohort

Machine-learning technologies can offer great opportunities in the process of screening for rare disease patients.

Analyzing through Big Data who may fit the testing criteria can expedite the diagnostic delay.

This can offer patients more effective therapy if started in the early stages of the disease.

Share this article:

More News & Highlights

News

First patients diagnosed with rare disease with assist of AI algorithm are fact in Bulgaria

Sqilline and a leading pharmaceutical company have partnered to apply AI algorithm and track for high-risk patients for the rare disease of Transthyretin amyloid polyneuropathy...

Read more...

Job Offer

Sqilline is looking for Key Account Manager Hospitals/Physicians

Company description Sqilline is a software and Clinical Research Organisation (CRO) that expertise in Big Data technology, machine learning algorithms, and AI. The company has built...

Read more...

News

Beyond the randomized clinical trials comes the real-world evidence

Sofia, November 14, 2022 – Dr. Gergana Shalamanova from the Oncology Center in Plovdiv showed the interesting comparison of Real-world Evidence (RWE) vs. Randomized Clinical...

Read more...